» Articles » PMID: 20869968

Implantation of Cardiac Progenitor Cells Using Self-assembling Peptide Improves Cardiac Function After Myocardial Infarction

Overview
Date 2010 Sep 28
PMID 20869968
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Implantation of various types of cells into the heart has been reported to be effective for heart failure, however, it is unknown what kinds of cells are most suitable for myocardial repair. To examine which types of cells are most effective, we injected cell-Puramatrix™ (PM) complex into the border area and overlaid the cell-PM patch on the myocardial infarction (MI) area. We compared cardiac morphology and function at 2 weeks after transplantation. Among clonal stem cell antigen-1 positive cardiac progenitors with PM (cSca-1/PM), bone marrow mononuclear cells with PM (BM/PM), skeletal myoblasts with PM (SM/PM), adipose tissue-derived mesenchymal cells with PM (AMC/PM), PM alone (PM), and non-treated MI group (MI), the infarct area of cSca-1/PM was smaller than that of BM/PM, SM/PM, PM and MI. cSca-1/PM and AMC/PM attenuated ventricular enlargement and restored cardiac function in comparison with MI. Capillary density in the infarct area of cSca-1/PM was higher than that of other five groups. The percentage of TUNEL positive cardiomyocytes in the infarct area of cSca-1/PM was lower than that of MI and PM. cSca-1 secreted VEGF and some of them differentiated into cardiomyocytes and vascular smooth muscle cells. These results suggest that transplantation of cSca-1/PM most effectively prevents cardiac remodeling and dysfunction through angiogenesis, inhibition of apoptosis and myocardial regeneration.

Citing Articles

Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells.

Clavellina D, Balkan W, Hare J Expert Opin Biol Ther. 2023; 23(10):951-967.

PMID: 37542462 PMC: 10837765. DOI: 10.1080/14712598.2023.2245329.


Pericardial Grafting of Cardiac Progenitor Cells in Self-Assembling Peptide Scaffold Improves Cardiac Function After Myocardial Infarction.

Kanda M, Nagai T, Kondo N, Matsuura K, Akazawa H, Komuro I Cell Transplant. 2023; 32:9636897231174078.

PMID: 37191272 PMC: 10192947. DOI: 10.1177/09636897231174078.


Cardiac stem cells: Current knowledge and future prospects.

Mehanna R, Essawy M, Barkat M, Awaad A, Thabet E, Hamed H World J Stem Cells. 2022; 14(1):1-40.

PMID: 35126826 PMC: 8788183. DOI: 10.4252/wjsc.v14.i1.1.


Biomaterials via peptide assembly: Design, characterization, and application in tissue engineering.

Gray V, Amelung C, Duti I, Laudermilch E, Letteri R, Lampe K Acta Biomater. 2021; 140:43-75.

PMID: 34710626 PMC: 8829437. DOI: 10.1016/j.actbio.2021.10.030.


Neurotrophin-3 contributes to benefits of human embryonic stem cell-derived cardiovascular progenitor cells against reperfused myocardial infarction.

Bi W, Wang J, Jiang Y, Li Q, Wang S, Liu M Stem Cells Transl Med. 2021; 10(5):756-772.

PMID: 33529481 PMC: 8046156. DOI: 10.1002/sctm.20-0456.